LifeStent™ Vascular Stent System
The LifeStent™ Vascular Stent System is part of the Bard portfolio supplied by BD. BD describes it as a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and popliteal artery. According to BD, the stent has a unique helical design engineered for bending, compression and torsion with dynamic vessel conformability, intended to withstand the mechanical demands of the femoropopliteal segment. BD reports substantial clinical experience with the platform, stating that the LifeStent™ Vascular Stent Systems in varying sizes have been studied in more than ten clinical trials in the United States and globally, with results that BD describes as showing sustained effectiveness up to three years and treatment superiority over balloon angioplasty. BD also states that it is the only commercially available bare metal stent FDA-approved for the superficial femoral and full popliteal arteries, and cites the longest lesion length indication among its features, with lesions up to 240 mm in length. For interventional and vascular surgery teams in Azerbaijan, the relevant interest is a well-studied nitinol stent for the femoropopliteal segment. Azmed Devices provides manufacturer documentation, registration status, tender support and supply coordination for BD peripheral vascular products. Detailed specifications and available configurations are available on request.
Размеры и технические характеристики
- Specifications
- Available on request
Производитель: C. R. Bard, Inc. (a BD company) · Источник данных: bd.com
Особенности изделия
Конструктивные характеристики согласно публикациям Bard.
Helical design
BD describes a unique helical design engineered for bending, compression and torsion with dynamic vessel conformability.
SFA and popliteal indication
BD states it is FDA-approved for the superficial femoral artery and full popliteal artery.
Long lesion coverage
BD cites the longest lesion length indication, treating lesions up to 240 mm in length.
Sustained effectiveness
BD states the stent has shown sustained effectiveness up to three years and treatment superiority over balloon angioplasty.
Extensive clinical study
BD reports the systems have been studied in more than ten clinical trials in the United States and globally.
Documentation
Official IFU, diameter and length matrix and full specifications are available on request through Azmed Devices.
Идентификация и технические характеристики изделия
Референсные идентификаторы для закупок, регистрации и тендерной документации.
| Производитель | C. R. Bard, Inc. (a BD company) |
|---|---|
| Бренд | Bard |
| Семейство продукции | Периферические сосуды |
| Доступность по странам | Азербайджан |
Клиническое применение
LifeStent™ Vascular Stent System — это self-expanding nitinol stent for the sfa and popliteal artery в семействе Периферические сосуды от C. R. Bard, Inc. (a BD company), применяемый специалистами по интервенционным вмешательствам в процедурах, где показано использование self-expanding nitinol stent for the sfa and popliteal artery данного класса.
Для получения полного перечня показаний к применению, противопоказаний и инструкции по применению (IFU) запросите официальную документацию Bard через нашу клиническую команду. Azmed Devices поставляет LifeStent™ Vascular Stent System больницам и клиникам по всему Азербайджану.
Загрузки и документация
Инструкция по применению (IFU), технические спецификации и клиническая литература для LifeStent™ Vascular Stent System доступны по запросу у нашей клинической команды.
Запросить документациюЧасто задаваемые вопросы
- Which vessels is the LifeStent Vascular Stent indicated for?
- BD describes it as a peripheral stent intended to improve luminal diameter in the native superficial femoral artery (SFA) and popliteal artery, and states it is FDA-approved for the SFA and full popliteal artery.
- What clinical evidence does BD cite?
- BD states the LifeStent™ systems have been studied in more than ten clinical trials in the US and globally, with sustained effectiveness up to three years and treatment superiority over balloon angioplasty.
- How can our hospital order LifeStent Vascular Stent System in Azerbaijan?
- Contact Azmed Devices at info@azmeddevices.com. We provide manufacturer documentation, registration status and tender support, and coordinate supply for BD technologies.
